Literature DB >> 12384554

Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines.

Kenichi Harada1, Shinichi Toyooka, Narayan Shivapurkar, Anirban Maitra, Jyotsna L Reddy, Hittu Matta, Kuniharu Miyajima, Charles F Timmons, Gail E Tomlinson, Domenico Mastrangelo, Robert J Hay, Preet M Chaudhary, Adi F Gazdar.   

Abstract

Methylation of the promoter regions of CpG-rich sites in genes is the major mechanism for the silencing of many genes in tumors. Methylation of the key apoptosis-related gene caspase 8 (CASP8) has been reported in some childhood tumors and in neuroendocrine lung tumors. We examined the methylation status of 181 pediatric tumors and found frequent methylation in rhabdomyosarcomas (83%), medulloblastomas (81%), retinoblastomas (59%), and neuroblastomas (52%). Methylation frequencies were low in Wilms' tumors (19%) and absent in hepatoblastomas, acute leukemias, osteosarcomas, Ewing's sarcomas, and ganglioneuromas and in normal tissues. Methylation of CASP8 and the tumor suppressor gene RASSF1A were highly significantly correlated in all tumor types by both the chi(2) and the Fisher's exact tests (P < 0.0001 for both tests). Because the region of the gene examined by us and others is not located in the promoter region and lacks features of a CpG island, we explored the relationship between methylation and gene silencing in detail using 23 pediatric tumor cell lines. Studies included relating the methylation of the region to gene expression at mRNA and protein levels, enzymatic assays of gene function, clonal analysis of PCR amplicons of the region, and exposure to a demethylating agent. These studies indicated that methylation correlated with the loss of gene function in most cases; however, other mechanisms of gene inactivation were present in some cases. Posttranscriptional inactivation of the closely related gene caspase 10 was present in many cell lines. Our results suggest that deregulation of the death receptor pathway to apoptosis is frequent in many types of pediatric tumors and their cell lines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384554

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  62 in total

1.  Escherichia coli succinic thiolinase. Stoichiometry of phosphorylation and coenzyme A binding.

Authors:  C M Bowman; J S Nishimura
Journal:  J Biol Chem       Date:  1975-07-25       Impact factor: 5.157

2.  Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA.

Authors:  Gabriella Livide; Maria Carmela Epistolato; Mariangela Amenduni; Vittoria Disciglio; Annabella Marozza; Maria Antonietta Mencarelli; Paolo Toti; Stefano Lazzi; Theodora Hadjistilianou; Sonia De Francesco; Alfonso D'Ambrosio; Alessandra Renieri; Francesca Ariani
Journal:  Pathol Oncol Res       Date:  2012-01-26       Impact factor: 3.201

Review 3.  In search of tumor suppressing functions of menin.

Authors:  Yuqing Yang; Xianxin Hua
Journal:  Mol Cell Endocrinol       Date:  2007-01-11       Impact factor: 4.102

4.  mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α.

Authors:  Hakan Cam; John B Easton; Anthony High; Peter J Houghton
Journal:  Mol Cell       Date:  2010-11-24       Impact factor: 17.970

Review 5.  Cellular mechanisms controlling caspase activation and function.

Authors:  Amanda B Parrish; Christopher D Freel; Sally Kornbluth
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-06-01       Impact factor: 10.005

6.  Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28.

Authors:  Ines Müller; Elwira Strozyk; Sebastian Schindler; Stefan Beissert; Htoo Zarni Oo; Thomas Sauter; Philippe Lucarelli; Sebastian Raeth; Angelika Hausser; Nader Al Nakouzi; Ladan Fazli; Martin E Gleave; He Liu; Hans-Uwe Simon; Henning Walczak; Douglas R Green; Jiri Bartek; Mads Daugaard; Dagmar Kulms
Journal:  Mol Cell       Date:  2020-01-22       Impact factor: 17.970

7.  Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.

Authors:  Bing Z Carter; Po Yee Mak; Duncan H Mak; Yuexi Shi; Yihua Qiu; James M Bogenberger; Hong Mu; Raoul Tibes; Hui Yao; Kevin R Coombes; Rodrigo O Jacamo; Teresa McQueen; Steven M Kornblau; Michael Andreeff
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 13.506

8.  Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.

Authors:  Ji Qian; Hui-Qi Qu; Lixin Yang; Ming Yin; Qiming Wang; Shaohua Gu; Qihan Wu; Xueying Zhao; Wenting Wu; Junjie Wu; Xiaoming Tan; Wenqing Chen; Haijian Wang; Jiucun Wang; Weiwei Fan; Hongyan Chen; Baohui Han; Daru Lu; Qingyi Wei; Li Jin
Journal:  Oncologist       Date:  2012-07-27

Review 9.  Identifying novel therapeutic agents using xenograft models of pediatric cancer.

Authors:  Raushan T Kurmasheva; Peter J Houghton
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-18       Impact factor: 3.333

10.  Additive effects of 5-aza-2'-deoxycytidine and irradiation on clonogenic survival of human medulloblastoma cell lines.

Authors:  Ina Patties; Jutta Jahns; Guido Hildebrandt; Rolf-Dieter Kortmann; Annegret Glasow
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.